2500 Stock Overview
Engages in the research, development, clinical development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Venus Medtech (Hangzhou) Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.62 |
| 52 Week High | HK$14.94 |
| 52 Week Low | HK$3.74 |
| Beta | 0.55 |
| 11 Month Change | 0% |
| 3 Month Change | -0.71% |
| 1 Year Change | -61.61% |
| 33 Year Change | -92.66% |
| 5 Year Change | n/a |
| Change since IPO | -92.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2500 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 0% | -0.5% | -2.1% |
| 1Y | -61.6% | -36.7% | 11.5% |
Return vs Industry: 2500 underperformed the Hong Kong Medical Equipment industry which returned -51.3% over the past year.
Return vs Market: 2500 underperformed the Hong Kong Market which returned -16.7% over the past year.
Price Volatility
| 2500 volatility | |
|---|---|
| 2500 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 10.0% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.1% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 2500 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2500's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,006 | Lin Haosheng Lim | www.venusmedtech.com |
Venus Medtech (Hangzhou) Inc. engages in the research, development, clinical development, manufacturing, and commercialization of transcatheter heart valve medical devices in Mainland China and internationally. The company’s products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension.
Venus Medtech (Hangzhou) Inc. Fundamentals Summary
| 2500 fundamental statistics | |
|---|---|
| Market cap | HK$2.46b |
| Earnings (TTM) | -HK$1.31b |
| Revenue (TTM) | HK$491.35m |
5.0x
P/S Ratio-1.9x
P/E RatioIs 2500 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2500 income statement (TTM) | |
|---|---|
| Revenue | CN¥452.11m |
| Cost of Revenue | CN¥101.03m |
| Gross Profit | CN¥351.07m |
| Other Expenses | CN¥1.56b |
| Earnings | -CN¥1.21b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.76 |
| Gross Margin | 77.65% |
| Net Profit Margin | -267.18% |
| Debt/Equity Ratio | 23.4% |
How did 2500 perform over the long term?
See historical performance and comparison